(Measles + rubella) vaccine is under clinical development by Indian Immunologicals and currently in Phase III for Rubella (German Measles). According to GlobalData, Phase III drugs for Rubella (German Measles) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Measles + rubella) vaccine LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Measles + rubella) vaccine overview
Vaccine candidate is under development for the prevention of measles and rubella. It is administered by subcutaneous route.
Indian Immunologicals overview
Indian Immunologicals (IIL), a subsidiary of National Dairy Development Board, manufactures and commercializes human health and animal health vaccines. The company provides human health vaccines for rabies, tetanus, diphtheria, pertussis, and hepatitis-B. Its underdevelopment product pipeline includes vaccines for hepatitis A, chikungunya, Japanese encephalitis, measles rubella, dengue, and others. IIL also provides animal health products such as vaccines; formulations including anti-infectives, anti-parasiticides, NSAIDs; nutraceuticals; over-the-counter (OTC), and generics. The company operates manufacturing units in India and New Zealand. IIL is headquartered in Hyderabad, Telangana, India.
For a complete picture of (Measles + rubella) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
